Popular search terms:
Search Results
77 results found-
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2025-2026-fluad-monograph-and-label.pdf -
FLUCELVAX® Trivalent Influenza Vaccine FLUCELVAX® Trivalent Influenza Vaccine QUAD TIV1c4 TIV2c4 QUAD TIV1c4 TIV2c4 N=663 N=330 N=327 N=656 N=340 N=336 Local Adverse Reactions Injection site 45 (<1) 37 (<1) 41 (0) 22 (0) 19 (0) 19 (0) pain Injection site 13 (0) 13 (0) 10 (0) 12 (0) 11 (0) 10 (0) erythema Injection site 12 (0) 10 (<1) 10 (0) 9 (0) 7 (0) 8 (0) induration Injection site 4 (0) 3 (<1) 5 (0) 5 (0) 4 (0) 5 (0) ecchymosis Systemic Adverse Reactions Headache 19 (<1) 19 (<1) 19 (<1) 9 (<1) 9 (<1) 8 (<1) Fatigue 18 (<1) 22 (<1) 16 (2) 9 (<1) 11 (<1) 9 (<1) Myalgia 15 (<1) 15 (<1) 15 (1) 8 (<1) 9 (<1) 8 (<1) Nausea 10 (<1) 7 (<1) 9 (1) 4 (<1) 4 (0) 4 (<1) Arthralgia 8 (<1) 8 (0) 10 (<1) 6 (<1) 5 (<1) 7 (<1) Loss of 8 (<1) 9 (<1) 8 (<1) 4 (<1) 5 (0) 4 (<1) appetite
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2025-2026-flucelvax-monograph-and-label.pdf -
CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season
https://www.cslseqirus.ca/news/canadian-audience-only -
CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.
https://www.cslseqirus.ca/news/idweek-2024 -
CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.
https://www.cslseqirus.ca/news/options -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.ca/ -
CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
https://www.cslseqirus.ca/news/avian